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Abstract

THE STUDY OF THE EFFECT OF DRUGS OF ABUSE ON PROTEIN KINASE A
ACTIVITY IN MOUSE BRAIN AND SPINAL CORD.
By George D. Dalton, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2005.
Dr. William L. Dewey, Professor, Department of Pharmacology & Toxicology

Morphine and A9-THC are drugs that produce analgesia and rewarding effects. However,
chronic treatment with morphine and

a9-THCproduces

problematic side-effects

including tolerance and physical dependence. The cellular mechanisms underlying opioid
and cannabinoid antinociceptive tolerance have been studied for years. Research has
demonstrated that the expression of morphine and A~-THCantinociceptive tolerance may
be mediated through intracellular signaling pathways, such as the adenylyl cyclase
/Protein Kinase A (PKA) cascade. The present study investigated the role of PKA in the
expression of morphine and a9-THC
antinociceptive tolerance. Male Swiss Webster mice
were treated chronically with morphine or A~-THCand the warm-water tail-flick test was
used to assess antinociception. These studies revealed that the level and the duration of
morphine

antinociceptive

tolerance

both

influenced

whether

PKA activity was increased in mouse brain and spinal cord. Cytosolic PKA activity was
increased in the thalamus of 3-day morphine-tolerant mice expressing a 45-fold level of
tolerance, but not in mice that expressed a 10-fold level of tolerance. In addition,
cytosolic PKA activity was increased in the lumbar spinal cord (LSC) of 15-day
morphine-tolerant mice. However, chronic treatment with A9-THC had no effect on
neuronal PKA activity even in mice that expressed a high level of antinociceptive
tolerance. The absence of an effect of chronic treatment with A9-THC on neuronal PKA
activity was supported by the development of a positive control in which the PKA
activator Sp-8-Br-CAMPS was administered intracerebroventricularly (i.c.v.) and
intrathecally (i.t.) in drug-naYve mice and increases in PKA activity were observed in
several brain regions and LSC. Finally, the i.c.v. injection of two peptide fragments of
native Protein Kinase A inhibitor (PKI) peptide, PKI-(6-22)-amide and PKI-(Myr- 14-22)amide, significantly reversed antinociceptive tolerance in mice treated chronically with
morphine. PKI-(6-22)-amide (i.c.v.) also inhibited PKA activity in brain regions
(thalamus, periaqueductal gray (PAG), and medulla) and LSC, which studies have shown
play a role in morphine-induced analgesia. Moreover, PKI-(6-22)-amide reduced the
increase in PKA activity in thalamus and LSC observed with chronic morphine treatment.
Overall, these studies provide evidence that PKA plays a role in morphine tolerance, but
not A~-THCtolerance at the doses and times tested.

